CD33 and acute myeloid leukemia: Since the first ADC, Mylotarg® (gemtuzumab ozogamicin), was approved in 2000 by the US Food and Drug Administration (FDA) against CD33-positive acute myeloid leukemia (AML), there have been 14 ADCs received market approval (20, 21), and over 100 ADCs are currently under clinical development.